Yue Shuai, Ju Mengran, Su Zhe
Department of Plastic and Reconstructive Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100144, China.
Department of Plastic and Reconstructive Surgery, Chengdu Badachu Medical Aesthetics Hospital, Chengdu, 610000, China.
Aesthetic Plast Surg. 2022 Feb;46(1):395-405. doi: 10.1007/s00266-021-02596-7. Epub 2021 Oct 5.
Postoperative facial scarring can be a significant psychological burden for patients to carry after surgery, often resulting in prolonged mental health dysfunction. Currently, there is no established method to prevent facial scar formation; however, there are several methods to prevent facial scar hyperplasia and improve scar quality. Botulinum toxin A (BTA) has been widely used due to its properties of muscle paralysis and known success in plastic surgery and cosmetology. This meta-analysis aimed to evaluate the efficacy of BTA in preventing postoperative facial scar hyperplasia and improving scar quality.
PubMed, MEDLINE, EMBASE, web of science, and Cochrane libraries were searched for randomized controlled trials (RCTs) (published before May 2021) wherein BTA was used for the treatment of facial scars. The efficacy and safety of BTA were evaluated by the following scales: the Vancouver Scar Scale (VSS), Visual Analog Scale (VAS), Observer Scar Assessment Scale (OSAS), Patient Scar Assessment Scale (PSAS), and Stony Brook Scar Evaluation Scale (SBSES); the BTA effect on scar width and complications was also assessed.
Ten RCTs involving 114 cases were included. Through quantitative analysis, the BTA injection group had a higher VAS score, lower VSS score, lower OSAS score, and smaller scar width. However, no significant difference was noted in the incidence of postoperative complications between the two groups.
This meta-analysis demonstrated that BTA can safely improve the appearance of postoperative facial scars by significantly inhibiting scar hyperplasia and improving scar quality.
This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
术后面部瘢痕对患者而言可能是一个沉重的心理负担,常常导致长期的心理健康功能障碍。目前,尚无既定的预防面部瘢痕形成的方法;然而,有多种方法可预防面部瘢痕增生并改善瘢痕质量。A型肉毒毒素(BTA)因其肌肉麻痹特性以及在整形手术和美容领域的成功应用而被广泛使用。本荟萃分析旨在评估BTA预防术后面部瘢痕增生及改善瘢痕质量的疗效。
检索了PubMed、MEDLINE、EMBASE、科学网和Cochrane图书馆,查找2021年5月之前发表的将BTA用于治疗面部瘢痕的随机对照试验(RCT)。通过以下量表评估BTA的疗效和安全性:温哥华瘢痕量表(VSS)、视觉模拟量表(VAS)、观察者瘢痕评估量表(OSAS)、患者瘢痕评估量表(PSAS)和石溪瘢痕评估量表(SBSES);还评估了BTA对瘢痕宽度和并发症的影响。
纳入了10项涉及114例患者的RCT。通过定量分析,BTA注射组的VAS评分更高、VSS评分更低、OSAS评分更低且瘢痕宽度更小。然而,两组术后并发症的发生率无显著差异。
本荟萃分析表明,BTA可通过显著抑制瘢痕增生和改善瘢痕质量来安全地改善术后面部瘢痕外观。
证据级别III:本刊要求作者为每篇文章指定证据级别。有关这些循证医学评级的完整描述,请参阅目录或在线作者指南www.springer.com/00266 。